Imipenem/Cilastatine Kabi (Cilastatin Sodium, Imipenem Monohydrate)

Imipenem/cilastatin, the active ingredient in Imipenem/Cilastatin Kabi, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats serious bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, skin and soft‑tissue infections, nosocomial pneumonia, and febrile neutropenia in hospitalized patients.

GNH USA supplies Imipenem/Cilastatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imipenem/cilastatin is a broad‑spectrum carbapenem antibiotic used for serious bacterial infections.

Complicated intra‑abdominal infections: provides bactericidal activity against mixed aerobic and anaerobic pathogens. Complicated urinary tract infections: eradicates Gram‑negative and Gram‑positive organisms resistant to other agents. Skin and soft‑tissue infections: treats severe cellulitis and wound infections caused by susceptible bacteria. Nosocomial pneumonia: effective against hospital‑acquired respiratory pathogens. Febrile neutropenia: used empirically to cover likely bacterial causes in neutropenic patients.

Adverse reactions may occur with any antimicrobial therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be self‑limiting or indicate altered gut flora. - Rash: erythematous skin eruption, often transient. - Injection site reactions: pain, erythema, or swelling at the infusion site.

Serious or Rare Side Effects: - Seizures: especially in patients with pre‑existing CNS disorders or high doses. - Clostridioides difficile‑associated diarrhea: severe colitis requiring medical attention. - Anaphylaxis: rapid onset of respiratory distress, hypotension, and urticaria. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: extensive skin detachment and mucosal involvement.

Careful assessment and monitoring are required before and during therapy. - Renal function: adjust dosing in patients with impaired renal clearance. - Seizure risk: monitor patients with a history of central nervous system disorders. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or β‑lactam antibiotics. - Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. - Drug interactions: review concomitant medications that may lower the seizure threshold. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/cilastatin may interact with several co‑administered drugs.

Major Interactions (Avoid): - Valproic acid: may reduce plasma concentrations of valproate, risking loss of seizure control. - Phenobarbital, phenytoin, carbamazepine: may increase the risk of seizures when combined. - Renal dehydropeptidase inhibitors: can raise imipenem levels, increasing toxicity.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function. - Loop diuretics: may enhance ototoxic risk when used with aminoglycosides. - Proton pump inhibitors: minimal impact but should be reviewed for overall gastric pH effects.